An N-terminal fragment of bactericidal/permeability-increasing protein protects against hemodynamic and metabolic derangements in rat Gram-negative sepsis

Journal of Endotoxin Research

Volumn 3, Issue 1, 1996, Pages 57-66

  Ammons, W Steve ^a   Mallari, Cornell ^a  

^a XOMA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDE; LIPOPOLYSACCHARIDE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HEMODYNAMICS; NONHUMAN; RAT; SEPSIS;

EID: 0029865050     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Sato T., Isoyama T., Tanaka J., Jones R.T., Cowley R.A., Trump B.F. The pathophysiology of septic shock: changes in hemodynamics in rats following live E. coli injection. An application of the thermodilution method for measurement of cardiac output. Adv Shock Res 1982; 7: 25-42.
2. Pass L.J., Schoerb P.R., Pearce F.J., Drucker W.R. Cardiopulmonary response of the rat to gram-negative bacteremia. Am J Physiol 1984; 246: H344-H350.
3. Natanson C., Danner R.L., Elin RJ. et al. Role of endotoxemia in cardiovascular dysfunction and mortality: Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 1989; 83: 243-251.
4. Pawlush D.G., Musch T.I., Banner S.M., Martin LF. Cardiac dysfunction in a rat model of chronic bacteremia. Circ Shock 1990; 31: 269-279.
5. Rokke O., Revhaug A., Osterud B., Giercksky K.E. Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: the effect of antibiotic administration. In: Levin J., Buller H.K., ten Cate J.W., van Deventer S.J.H., Sturk A., eds. Bacterial Endotoxins: Pathophysiological Effects, Clinical Significance, and Pharmacological Control. Prog Clin Biol Res, vol 292. New York: Alan R Liss, 1988: 247-262.
6. Walsh C.J., Sugerman H.J., Mullen P.G. et al. Monoclonal antibody to tumor necrosis factor attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg 1992; 127: 138-145.
7. Lechner A.J., Ryerse J.S., Matuschak G.M. Acute lung injury during bacterial or fungal sepsis. Microscopy Res Tech 1993; 26: 444-456.
8. Wolfe R.R., Burke J.F. Glucose and lactate metabolism in experimental septic shock. Am J Physiol 1978; 235: R219-R227.
9. Jones S.B., Westfall M.V., Sayeed M.M. Plasma catecholamines during E. coli bacteremia in conscious rats. Am J Physiol 1988; 254: R470-R477.
10. Donaldson M.D.J., Vesey C.J., Bouloux P.M., Watson J.D., Besser G.M., Hinds C.J. Plasma catecholamine levels in porcine Escherichia coli septicaemia and following treatment with buprenorphine or naloxone. Circ Shock 1993; 39: 169-177.
11. de Boer J.P., Creasy A.A., Chang A. et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal and sublethal dose of Escherichia coli. Circ Shock 1993; 39: 59-67.
12. Tracey K.J., Fong Y., Hesse D.G. et al. Anti-cachetin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
13. Bagby G.J., Plessala K.J., Wilson L.A., Thompson J.J., Nelson S. Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163: 83-88.
14. Zanetti G., Heumann D., Gerain J. et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 1992; 148: 1890-1897.
15. Bengtsson A., Redl H., Paul E., Schlag G., Molines T.E., Davies J. Complement and leukocyte activation in septic baboons. Circ Shock 1993; 39: 83-88.
16. Parillo J.E., Parker M.M., Natanson C. et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Int Med 1990; 113: 227-242.
17. Fischer E., Marano M.A., Van Zee K.J. et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551-1557.
18. Fink M.P., Morrissey P.E., Stein K.L., Clement R.E., Fiallo V., Gardiner W.M. Systemic and regional hemodynamic effects of cyclooxygenase and thromboxane synthetase inhibition in normal and hyperdynamic endotoxemic rabbits. Circ Shock 1988; 26: 41-57.
19. 7]-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxin shock. Circ Shock 1989; 27: 93-101.
20. Morrison D.C., Ryan J.L. Endotoxins and disease mechanisms. Annu Rev Med 1987; 38: 417-476.
21. van Deventer S.J.H., Buller H.R., ten Cate J.W., Sturk A., Pauw W. Endotoxemia: an early predictor of septicaemia in febrile patients. Lancet 1988; 1: 605-609.
22. Animons W.S., Kung A.H.C. Recombinant amino terminal fragment of bactericidal/permeability increasing protein prevents hemodynamic responses to endotoxin. Circ Shock 1993; 41: 176-184.
23. Kohn F.R., Ammons W.S., Horwitz A. et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability increasing protein in experimental endotoxemia. J Infect Dis 1993; 168: 1307-1310.
24. Meszaros K., Parent J.B., Gazzano-Santoro H. et al. A recombinant amino terminal fragment of bactericidal/permeability increasing protein inhibits the induction of leukocyte responses by LPS. J Leukocyte Biol 1993; 54: 558-563.
25. Betz-Corradin S., Heumann D., Gallay P., Glauser M.P. Bactericidal/permeability-increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide. J Infect Dis 1994; 169: 105-111.
26. 23) inhibits soluble CD14-mediated LPS-induced endothelial adherence for human neutrophils. Shock 1994; 2: 81-88.
27. Lin Y., Ammons W.S., Leach W.J., Kung A.H.C. Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock 1994; 2: 324-331.
28. Lin Y., Kohn F.R., Kung A.H.C., Ammons W.S. Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor- elevation in rat endotoxemia. J Biochem Pharmacol 1994; 43: 1553-1559.
29. Meszaros K., Aberle S., Dedrick R. et al. Monocyte tissue factor induction by lipopolysaccharide [LPS]: dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability increasing protein. Blood 1994; 83: 2516-2525.
30. VanderMeer T.J., Menconi M.J., O'Sullivan B.P. et al. Bactericidal/permeability increasing protein ameliorates acute lung injury and neutrophil activation in porcine endotoxemia. J Appl Physiol 1994; 76: 2006-2014.
31. Kohn F.R., Kung A.H.C. Role of endotoxin in acute inflammation induced by gram-negative bacteria: specific inhibition of lipopolysaccharide-mediated responses with an amino-terminal fragment of bactericidal/permeability-increasing protein. Infect Immun 1995; 63: 333-339.
32. Marra M.N., Wilde G.G., Collins M.S., Snable J.L., Thornton M.B., Scott R.W. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532-537.
33. Kelly C.J., Cech A.C., Argenteanu M. et al. Role of bactericidal permeability increasing protein in the treatment of gram-negative pneumonia. Surgery 1993; 114: 140-146.
34. Ammons W.S., Kohn F.R., Kung A.H.C. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties. J Infect Dis 1994; 170: 1473-1482.
35. Rogy M.A., Moldawer L.L., Oldenburg H.S.A. et al. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg 1994; 220: 77-85.
36. Rogy M.A., Oldenburg H.S.A., Calvano S.E. et al. The role of bactericidal/ permeability-increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol 1994; 14: 120-133.
37. Mannion B.A., Weiss J., Elsbach P. Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli. J Clin Invest 1990; 86: 631-641.
38. Elsbach P., Weiss J. Phagocytic cells: oxygen-independent antimicrobial systems In: Gallin J.I., Goldstein I.M., Snyderman R., eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1992; 603-636.
39. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by bacteria. J Clin Invest 1992; 90: 1122-1130.
40. Gazzano-Santoro H., Parent J.B., Grinna L et al. High affinity binding of the bactericidal/permeability increasing protein (nBPI55) and a recombinant amino terminal fragment (rBPI23) to the lipid A region of LPS. Infect Immun 1993; 60: 4754-4761.
41. Kohn F.R., Philips G.L., Klingemann H.G. Regulation of tumor necrosis factor-α production and gene expression in monocytes. Bone Marrow Transplant 1992; 9: 369-376.
42. Whitworth P.W., Cryer H.M., Garrison R.N., Baumgarten T.E., Harris P.D. Hypoperfusion of the intestinal microcirculation without decreased cardiac output during live Escherichia coli sepsis in rats. Circ Shock 1989; 27: 111-122.
43. Silva A.T., Appelmilk B.J., Buurman W.A., Bayston K.F., Cohen J. Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanism independent of tumor necrosis factor and interleukin-6. J. Infect Dw 1990; 162: 454-459.
44. Plotkowski M-C., Saliba A.M., Pereira L.H.M., Cervante M.P., Bajolet-Laudinat O. Pseudomonas aeruginosa selective adherence to and entry into human endothelial cells. Infect Immun 1994; 62: 5456-5463.